{
    "id": 80192,
    "name": "relapsed/refractory diffuse large B-cell lymphoma",
    "source": "DOID",
    "definition": "A diffuse large B-cell lymphoma characterized by less than 50 percent decrease in lesion size with induction therapy or the appearance of new lesions or the appearance of new lesions after attainment of complete remission. [url:https\\://www.ncbi.nlm.nih.gov/pubmed/22160081]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080192",
    "evidence": [
        
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03340766",
            "title": "Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5839,
                    "therapyName": "Blinatumomab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03401853",
            "title": "Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3279,
                    "therapyName": "Pembrolizumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03579927",
            "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 6213,
                    "therapyName": "iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                },
                {
                    "id": 7797,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03642626",
            "title": "MT2017-45: CAR-T Cell Therapy for Heme Malignancies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7940,
                    "therapyName": "Cyclophosphamide + Fludarabine + Tisagenlecleucel",
                    "synonyms": null
                },
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03666988",
            "title": "First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9261,
                    "therapyName": "GSK3368715",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03684694",
            "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7850,
                    "therapyName": "Ibrutinib + Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03688152",
            "title": "A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7692,
                    "therapyName": "INCB053914 + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03736616",
            "title": "Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1605,
                    "therapyName": "Acalabrutinib",
                    "synonyms": null
                },
                {
                    "id": 3359,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 7647,
                    "therapyName": "Acalabrutinib + Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": "Acalabrutinib + R-ICE"
                }
            ]
        },
        {
            "nctId": "NCT03798314",
            "title": "Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7707,
                    "therapyName": "Nivolumab + Pomalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04156828",
            "title": "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8925,
                    "therapyName": "Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04220008",
            "title": "Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9202,
                    "therapyName": "Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 9201,
                    "therapyName": "Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04285268",
            "title": "Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9428,
                    "therapyName": "Bortezomib + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        }
    ]
}